Nasdaq exas.
In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% against a 9.1% decline of the industry and a 4.7% decline of the S&P 500 composite. The renowned global medical device company has ...
Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...EXAS Stock 12 Months Forecast. $95.46. (50.43% Upside) Based on 14 Wall Street analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $95.46 with a high forecast of $120.00 and a low forecast of $80.00. The average price target represents a 50.43% change from the last price of $63.46.Exact Sciences world-class team is the driving force behind the most innovative growth engine in cancer diagnostics. Our scientists are using advanced technologies to harness the power of DNA, RNA ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...
Investing in Exact Sciences (NASDAQ:EXAS) a year ago would have delivered you a 59% gain. Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders might be concerned after seeing the share price ...Exact Sciences Corp. (NASDAQ:EXAS) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more …Feb 27, 2018 · ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona.
Share $67.49 Nov 29, 10:10:29 AM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Apple Inc $191.11 AAPL0.37% Pacific Biosciences of California Inc $8.85 PACB2.55% Amazon.com Inc $147.18... These dynamics opened the door for Exact Sciences (NASDAQ:EXAS) to serve a rapidly expanding subsector of the healthcare industry by developing and commercializing novel molecular diagnostic tests ...
Exact Sciences (NASDAQ: EXAS) stock had tumbled nearly 27% over the last six months. Yet the company reported strong third-quarter financial results on Nov. 1 and has multiple strong positive ...Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...Find the latest on short interest for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.20.11.23 NASDAQ Composite Index-Wert EXACT Sciences-Aktie: So viel Gewinn hätte eine EXACT Sciences-Investition von vor 10 Jahren eingebracht 06.11.23 …WebNov 27, 2023 · Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?
"Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...
Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript Operator: Good afternoon, ladies and gentlemen, and welcome to the Exact Sciences Third Quarter 2023 Earnings Conference Call.
Oct 8, 2023 · Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ... Get the latest Exact Sciences Corporation (EXAS) stock news and headlines to help you in your trading and investing decisions.Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...... Back to EXAS Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following …WebNov 25, 2023 · Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...
TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Nov 30, 2023Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...Sep 6, 2023 · After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ... Dec 1, 2023 · Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Tuesday, August, 1st. The medical research company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.05. The medical research company earned $622.10 million during the quarter, compared to the consensus estimate of $601.14 ... Exact Sciences Corp. (NASDAQ:EXAS) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more …Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.
Dec 4, 2023 · December 4, 2023. Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. ( NASDAQ:EXAS - Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 530,134 shares of the medical research company's stock after selling 217,832 shares during the period.
One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 0.09%, and its shares gained 105.65% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...Oct 19, 2023 · "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ... Exact Sciences Corporation Common Stock (EXAS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.May 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ... Turning to the calls side of the option chain, the call contract at the $39.00 strike price has a current bid of $3.40. If an investor was to purchase shares of EXAS stock at the current price ...Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137!This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%.At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new October 28th contracts and identified one put and one call contract of particular ...The first of my AI stock recommendations is Exact Sciences (NASDAQ: EXAS).Maybe the chatbot knew that Cathie Wood likes the stock.But even if it didn’t, biotechnology (biotech) stocks are a good ...
Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO, and Jeff Elliott, our Chief Financial Officer ...
EXACT Sciences Corporation (NASDAQ:EXAS) Number of Hedge Fund Holders: 28. Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products ...
1. Exact Sciences Corp. (EXAS) In 2023, it is Exact Sciences that is the largest holding in Cathie Wood’s ARKK flagship ETF, and not Tesla. It is 9.7% of the portfolio. Exact Sciences has been ...Exact Sciences Corporation’s EXAS legacy Screening business is witnessing significant improvement, buoyed by Cologuard volume growth. However, escalating costs and stiff competition are concerning.1. Exact Sciences Corp. (EXAS) In 2023, it is Exact Sciences that is the largest holding in Cathie Wood’s ARKK flagship ETF, and not Tesla. It is 9.7% of the portfolio. Exact Sciences has been ...Exact Sciences Corporation EXAS is set to report second-quarter 2022 results on Aug 2, after the closing bell. In the last reported quarter, the company reported a net loss of $1.04, which was ...Exact Sciences Corporation EXAS recently presented modeling data that shows Cologuard (mt-sDNA) as the most cost-effective colorectal cancer (CRC) detection and screening option at the 2021 ...Nov 9, 2022 · EXACT Sciences Corporation (NASDAQ:EXAS) Number of Hedge Fund Holders: 28. Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products ... Get the latest Exscientia PLC (EXAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have added about 2.5% in that time frame, underperforming the S&P …Web3 Nov 2023 ... Exact Sciences Corporation [EXAS] Rings the Nasdaq Closing Bell | LIVE 07:29 Nasdaq MarketSite 3n #2.91% ЕХАСТ SCIENCES MAtaria Mvesday ...
Feb 16, 2021 · MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The ... Exact Sciences' sales will top $2 billion this year as the business continues to achieve impressive growth. ... NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03.Exact Sciences EXAS stock price today per share is 67.03 USD. How to purchase Exact Sciences stock? You can buy EXAS shares on the NasdaqCM exchange. Contact ...Instagram:https://instagram. sirius pricesbest real time stock chartsquarter dollar 1776 1976 valorhyt NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03. ... 10 stocks we like better than Exact Sciences When o ur analyst team has a stock tip, ... best individual health insurance nyc10 000 bill us Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. option trading game MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020.Dec 16, 2022 · 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower. 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in ...